Cronos Remains Undervalued Despite A Strong Balance Sheet And International Growth (NASDAQ:CRON)

The cannabis sector remains weak due to uncertainty over rescheduling. Cronos (CRON) reported strong financial performance for Q4 back in February. The company reported record revenue and an expanding international footprint. The company will acquire CanAdelaar, a Netherlands cannabis producer. Cronos maintains a strong balance sheet with no Welcome to the home of The Cannabis Report. I cover the cannabis sector and other sectors. I am most interested in technical stock analysis, option strategies, small cap strategies, and emerging markets. Feel free to contact me with any questions about publicly traded stocks in the cannabis industry. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. CRON's $831.8M in cash and no debt provide ample financial flexibility to pursue acquisitions like CanAdelaar and expand internationally with minimal balance sheet risk.